CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 408 enrolled
Drug / intervention
Meloxicam +1 moredrug
Likely dose
Meloxicam 7.5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01430559
NCT01430559N/ACompleted
CompareCT.gov

A DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL GROUP STUDY OF THE EFFECT OF MELOXICAM IN MAINLAND CHINESE SUBJECTS WITH OSTEOARTHRITIS (OA) OF THE KNEE

Pfizer·interventional·Posted Sep 8, 2011·Updated Dec 31, 2020

In Brief

A clinical study evaluating Meloxicam and Placebo for Osteoarthritis of the Knee. Completed, enrolled 408 participants across 25 sites.

Detailed Summary

This study is to validate the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) tool in mainland Chinese patients with osteoarthritis of the knee . This study will also evaluate the effects of Mobic versus placebo on reducing the symptoms of osteoarthritis in this population.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoarthritis of the Knee
CountriesChina
Collaborators--

Timeline

N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedSep 8, 2011
Enrollment StartOct 24, 2011
Primary CompletionMar 27, 2013
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 14.8 years ago

Interventions

Meloxicamdrug

7.5mg x2 once a day for 12 weeks

Placebodrug

Study subjects will be randomized to two treatment groups: one with Meloxicam 7.5 mgx2 once a day and another one with placebo. The duration of the interventional treatment is 12 weeks.